GenScript Biotech’s contract development and manufacturing (CDMO) business, GenScript Pro-Bio, and Eutilex have entered into a collaboration on plasmid and virus process development and manufacturing for multiple CAR-T programs in order to accelerate the development of global immunotherapy.
 
Eutilex will use GenScript’s one-stop plasmid and virus platform for plasmid and virus process development and manufacturing in its CAR-T programs. Supported by Eutilex’s immuno-therapy technology and GenScript ProBio’s experience in plasmid and virus manufactur-ing, this collaboration will expedite the launch of cell therapy products.
 
“We look forward to collaborating with GenScript ProBio,” said Byoung Kwon, chairman, Eutilex. “Eutilex is committed to providing better therapeutics to cure the incurable human diseases. While we have exclusive core technology, we also need to cooperate with experienced partners like GenScript ProBio to help advance projects. We expect to provide more therapeutics for more patients through close collaboration.”
 
Brian Min, chief executive officer, GenScript ProBio, said, “Eutilex is a cell therapy leader in South Korea due to its unique technology. We are very pleased to cooperate with an innovative enterprise like Eutilex with cutting-edge technology. GenScript ProBio is com-mitted to accelerating the commercialization of cell therapy and helping enterprises ex-pedite the launch of cell therapy products. Drawing on each other’s advantage through this collaboration, we move closer towards our goals. Relying on GenScript ProBio quali-ty system and our plentiful experience in plasmid and virus process manufacturing, we have multiple ongoing cell therapy programs under plasmid and virus process manufac-turing.”